FOLR1 and keratitis: Clinical studies reported various corneal changes, including keratitis, epithelial thinning, and microcyst formation, in patients treated with ADCs such as belantamab mafodotin (anti-BCMA), tisotumab vedotin (anti-TF), and Elahere (anti-FRα) [13].